Maternal-Health Startups Raised $978M. Few Accepted Medicaid.
Quick Breakdown · Maternal Health
Investors put $977.5 million into 172 venture-backed maternal-health startups between 2014 and 2022. A University of Pennsylvania research team analyzed that entire portfolio and found a consistent pattern in what the money went toward and who it was designed to serve.
The single largest slice — $520 million — went to maternal and fetal diagnostics. The most common company type was virtual or hybrid “wraparound” pregnancy care: apps, platforms, and navigator services layered on top of the existing system.
Medicaid pays for more than 40% of births in the United States. Few of the startups in the study accepted it.
The researchers also looked at whether the startups addressed maternal mortality directly. Most did not. The pitch decks and product descriptions circled around experience, convenience, and monitoring.
Keep reading — it’s free
Join 6,000+ readers. Women’s health research, translated clearly. Every Tue & Thu.
No spam. Unsubscribe anytime.
The researchers also looked at whether the startups addressed maternal mortality directly. Most did not. The pitch decks and product descriptions circled around experience, convenience, and monitoring — real gaps, but not the gaps where women are dying. Black maternal mortality, hemorrhage, hypertensive disorders, and failures of postpartum follow-up are where the US maternal death toll concentrates. The capital went elsewhere.
The pattern reflects a structural dynamic in health tech investment: ventures that serve commercially insured patients generate returns that ventures serving Medicaid populations do not. That calculus is rational from an investor perspective. The result is a market-shaped version of the same access gaps that public policy has failed to close through other means.
Source: JAMA Health Forum